/ JAMA
Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.
Kozhuharov N, Goudev A, Flores D, Maeder MT, Walter J, Shrestha S, Gualandro DM, de Oliveira Junior MT, Sabti Z, Müller B, Noveanu M, Socrates T, Ziller R, Bayés-Genís A, Sionis A, Simon P, Michou E, Gujer S, Gori T, Wenzel P, Pfister O, Conen D, Kapos I, Kobza R, Rickli H, Breidthardt T, Münzel T, Erne P, Mueller C; GALACTIC Investigators.
JAMA
2019 Dec 17;322(23):2292-2302. doi: 10.1001/jama.2019.18598
This publication focuses on improving the treatment of patients with acute heart failure. It presents the main results of the GALACTIC study, the world's largest company-independent therapy study for patients with acute heart failure. The results make it clear that, contrary to the assumption of many researchers and clinicians, early and high-dose administration of vasodilators could not increase the survival rate of patients with acute heart failure.